At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
-
Sep 17, 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present preclinical data on the...
-
Aug 28, 2018
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 10:00 AM EDT in the Lotte New York Palace Hotel in...
-
Aug 3, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter results. "We are pleased with the preliminary results of the three-part Phase 1/1b clinical trial of Pulmazole. The data supports...
-
Jul 23, 2018
Members include experts in both clinical research and management of Allergic Bronchopulmonary Aspergillosis and Asthma
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the formation of the...
-
Jul 17, 2018
Single dose of Pulmazole safe and well tolerated in subjects with asthma
Pulmatrix, Inc. (NASDAQ: PULM) announced today that all dosing and follow up visits have been completed for Part 3 of the ongoing first-in-human study of Pulmazole (PUR1900) - an inhaled iSPERSETM...
-
Jun 25, 2018
All doses were well tolerated in normal healthy volunteers in Parts 1 and 2 at up to 35 mg of itraconazole, the maximal dose planned
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today top-line results for the...
-
Jun 13, 2018
Data published in the British Journal of Clinical Pharmacology demonstrate that PUR0200 achieves similar improvements in lung function to Spiriva® HandiHaler® at significantly lower doses
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the publication of data...
-
Jun 7, 2018
No Imminent Plan to Effect Reverse Stock Split
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that each of the following...
-
May 17, 2018
Company will also present pre-clinical data on RV1162 (PUR1800) at the affiliated American Thoracic Society 2018 International Conference in San Diego
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases has been selected to present at the 2018...
-
May 11, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter results. "We reached a major milestone for our Pulmazole program in the first quarter with the initiation of dosing in our phase 1/1b...
-
Mar 29, 2018
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of an underwritten public offering of an aggregate of 23,500,000 units. Each unit is...
-
Mar 13, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2017 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary disease development pipeline. "The Company...
-
Feb 12, 2018
Phase 1 data is expected in mid-2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that the single dose...
-
Jan 24, 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it will present new...
-
Jan 22, 2018
Screening of subjects for this first-in-human study has begun and represents an important milestone in advancing this first in class therapy to the clinic
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it has received...
-
Nov 9, 2017
Completed Out-License Agreement for PUR0200 US Rights and Received Award to Advance Development of Pulmazole
Pulmatrix, Inc. (NASDAQ: PULM) today reports its third quarter financial results and provided an overview of recent operational highlights. "During the third quarter, we made significant progress...
-
Oct 31, 2017
Preclinical data show that Pulmatrix's inhaled antifungal drug can achieve high concentrations in the lungs, with low levels in the bloodstream
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it will present...
-
Oct 30, 2017
Dr. Roach will help Pulmatrix accelerate the development of its innovative inhaled drugs
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has appointed...
-
Oct 3, 2017
The FDA designation provides five years of market exclusivity for Pulmatrix's inhaled product for treating fungal infections in the lungs of patients with allergic bronchopulmonary aspergillosis
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that its drug candidate...
-
Sep 21, 2017
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 2:15 PM EDT in the Intercontinental New York Barclay Hotel in...
-
Sep 20, 2017
The patents broaden the protection and potential applications for Pulmatrix's innovative inhaled drug delivery platform and most advanced drug candidate
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received two...
-
Sep 8, 2017
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 10:25 AM EDT in the Lotte New York Palace Hotel in New...
-
Sep 6, 2017
The agreement will accelerate the development of the innovative inhaled drug
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has partnered with...
-
Sep 5, 2017
The Award Supports Advancement of PUR1900 to Phase 1/1B Clinical Trial in 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received an...
-
Aug 4, 2017
Strengthened Board of Directors and Completed In-License Agreement
Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter financial results and provided an overview of recent operational highlights. "During the second quarter, we further strengthened our...
-
Jun 15, 2017
Mr. Munshi brings over 25 years of executive leadership experience in biotechnology and pharmaceuticals to help Pulmatrix move through the next stage of company development.
Pulmatrix, Inc. (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs for major lung diseases, has announced the appointment of Amit D. Munshi to the Pulmatrix Board of...
-
Jun 13, 2017
The novel compounds target an enzyme involved in both inflammation and cancer, and may offer a new approach for treating respiratory diseases
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into...
-
Jun 9, 2017
NASDAQ:PULM Pulmatrix (NASDAQ:PULM) is a Lexington, MA based clinical stage biopharmaceutical company developing innovative inhaled products to address unmet medical needs in serious pulmonary...
-
May 9, 2017
The patent gives Pulmatrix intellectual property protection for the drug until 2033
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received a key...
-
May 5, 2017
Pulmatrix, Inc. (NASDAQ: PULM) today reports its first quarter financial results. "During the first quarter, we continued to make progress across our iSPERSE-based development pipeline of inhaled...
-
May 3, 2017
- Will Develop and Execute Commercial and Business Development Strategies -
Pulmatrix, Inc. (NASDAQ: PULM) a clinical stage biotechnology company developing inhaled therapies for the treatment of significant unmet needs in respiratory diseases, today announced the...
-
Mar 27, 2017
The world-leading experts will help accelerate the development of PUR1900, Pulmatrix's innovative inhaled drug for fungal infections in the lungs
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has added two...
-
Mar 21, 2017
The patent extends Pulmatrix's broad protection for its innovative technology to Europe
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received a key...
-
Mar 10, 2017
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2016 financial results, reviews the Company's recent progress, and provides an outlook for 2017 for its pulmonary disease development pipeline. "The...
-
Feb 3, 2017
Pulmatrix, Inc., (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into...
-
Jan 30, 2017
Pulmatrix, Inc., (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into...
-
Jan 17, 2017
The FDA designation adds five years of market exclusivity for Pulmatrix' inhaled product for treating fungal infections in the lungs of CF patients
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that its drug candidate...
-
Dec 19, 2016
The patents significantly broaden protection for the technology--and for its use to treat a wide variety of diseases
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received five...
-
Nov 29, 2016
In wide-ranging interview, Hava discusses advances in treating respiratory diseases using inhaled drugs, among other topics
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that its Chief Scientific...
-
Nov 4, 2016
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced it third quarter financial...
-
Oct 11, 2016
New study shows that Pulmatrix's inhaled drug delivery platform successfully delivers higher doses of an antifungal drug to the lungs compared to oral delivery.
Pulmatrix, Inc. (NASDAQ: PULM) will present promising new preclinical data about its inhaled antifungal drug PUR1900 in a poster at the North American Cystic Fibrosis Conference. "The preclinical...
-
Oct 3, 2016
Dr. Sherman's extensive experience in developing drugs in oncology and other therapeutic areas will help Pulmatrix target more diseases, potentially including cancer.
Pulmatrix, Inc. (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs, announced today that the company has appointed Matthew L. Sherman, M.D., Executive Vice President and...
-
Sep 23, 2016
Recent white paper by Envigo explains the advantages of delivering drugs to the lungs--and describes how this delivery method is increasingly being used for a wide variety of diseases
Pulmatrix, Inc. (NASDAQ: PULM) today announced that a recent white paper, What is the future of inhalation delivery?, by global research and consulting firm Envigo predicts rapid growth for drugs...
-
Sep 7, 2016
Pulmatrix, Inc. (NASDAQ: PULM) will give a presentation at the 2016 Aegis Growth Conference at The Encore at Wynn Las Vegas in Nevada on Wednesday, September 21, 2016 at 10:00 AM PDT. Pulmatrix...
-
Aug 31, 2016
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 5:30 PM EDT in the Lotte New York Palace Hotel in New...
-
Aug 17, 2016
The designation by the FDA is based on the hypothesis that Pulmatrix's drug may be superior to existing treatments. It creates a quicker regulatory path to market while also providing financial incentives.
Pulmatrix, Inc. (NASDAQ: PULM) announced today that the U.S. Food & Drug Administration has granted the company's request for orphan drug status for its inhaled drug for treating pulmonary fungal...
-
Aug 4, 2016
Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter financial results and provides an update on the progress of its drug development pipeline. "In the first half of the year, we...
-
Jul 19, 2016
Data Support Continued Development Towards Pivotal Bioequivalence Program for European Registration
Pulmatrix, Inc. (NASDAQ: PULM), today announced positive topline data from a Phase 1 pilot pharmacokinetic bioavailability trial of PUR0200. PUR0200 is a novel dry powder formulation of a...
-
Jul 6, 2016
In an interview with News Medical, Pulmatrix CEO Robert Clarke explains how innovative dry powders enable drugs to be delivered to the lungs more efficiently
Pulmatrix, Inc. (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs, today announced that Chief Executive Officer Robert Clarke, PhD, has described advances in inhaled...
-
Jun 27, 2016
Pulmatrix, Inc., (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs today announced the release of an animated life sciences video [ir.pulmatrix.com] to raise awareness...
|
home about pulmatrix platform pipeline investors careers contact site design